Global Polio Resurgence is a key topic under Social Issues for UPSC Civil Services Examination. Key points include: Global polio resurgence is a critical concern, with recent detections in Pakistan, Cameroon, and European nations.. New research suggests poliovirus may be primarily transmitted via the respiratory route, challenging traditional understanding.. Oral Polio Vaccine (OPV) can lead to vaccine-derived poliovirus (cVDPV) outbreaks, complicating eradication efforts.. Understanding this topic is essential for both UPSC Prelims and Mains preparation.
Global Polio Resurgence is a Medium-level topic in UPSC Social Issues. It is tested in both Prelims (factual MCQs) and Mains (analytical answer writing). Previous year UPSC questions have frequently covered aspects of Global Polio Resurgence, making it essential for comprehensive IAS preparation.
To prepare Global Polio Resurgence for UPSC: (1) Study the comprehensive notes covering all key concepts on Vaidra. (2) Practice previous year questions on this topic. (3) Connect it with current affairs using daily updates. (4) Revise using key takeaways and mind maps available for Social Issues. (5) Write practice answers linking Global Polio Resurgence to related GS Paper topics.

The World Health Organization (WHO) recently confirmed the presence of poliovirus in several nations, indicating an ongoing challenge to global eradication efforts. Countries like Pakistan, Cameroon, and various European nations have reported these detections.
📍 Recent Detections: Poliovirus identified in Pakistan, Cameroon, and several European nations by WHO, highlighting persistent circulation.
Traditional understanding suggested poliovirus primarily spreads via the faecal-oral route. However, recent research indicates a potential shift in the primary mode of transmission.
New findings suggest that the virus may be predominantly transmitted through the respiratory route. This challenges long-held assumptions and has implications for public health strategies.
💡 Key Shift: Poliovirus transmission may be primarily via the respiratory route, not just the traditional faecal-oral route, impacting containment strategies.
Recent assessments underscore the critical need to transition towards the Inactivated Polio Vaccine (IPV). IPV is considered non-transmissible and offers robust protection against poliovirus-induced paralysis.
The Oral Polio Vaccine (OPV), while effective, has been associated with outbreaks of vaccine-derived poliovirus cases (cVDPV). These cases significantly complicate global eradication efforts by reintroducing the virus.
⚡ UPSC Insight: The shift from OPV to IPV and the challenges of cVDPV are crucial topics for GS Paper II (Health) and GS Paper III (Science & Technology), often appearing in questions on public health policy.
Polio, or poliomyelitis, is a highly contagious viral disease. It predominantly affects children under five years of age, making them particularly vulnerable.
The virus invades the nervous system, potentially leading to paralysis. It traditionally spreads through the faecal-oral route or via contaminated food and water.
🦠 Polio Definition: A highly contagious viral disease, mainly affecting children under five, capable of causing paralysis by invading the nervous system.
There are three distinct and immunologically individual wild poliovirus strains. These strains are categorized based on their antigenic properties.
Several types of vaccines have been developed to combat polio, each with different characteristics and applications in eradication strategies.
📅 OPV Switch (April 2016): A global initiative to replace tOPV with bOPV. This was critical as WPV2 had been eradicated, and tOPV’s Type 2 component was the source of most cVDPV2 outbreaks.
| Feature | Inactivated Polio Vaccine (IPV) | Oral Polio Vaccine (OPV) |
|---|---|---|
| Virus Type | Contains inactivated (dead) virus particles. | Contains live, attenuated (weakened) poliovirus. |
| Risk of Vaccine-derived Polio | No risk of causing vaccine-induced polio. | Rare risk of reversion to a virulent form, causing cVDPV outbreaks. |
| Safety for Immunocompromised | Safe for individuals with weakened immune systems. | Not safe for immunocompromised individuals due to live virus. |
| Immunity Duration | Provides durable immunity, but requires multiple boosters. | Immunity may be shorter-lasting, potentially requiring additional doses. |
| Mucosal Immunity | Limited mucosal immunity, less effective at preventing virus transmission. | Strong mucosal immunity (especially in intestines), reducing virus transmission. |
| Cost | Higher cost to produce and administer. | Lower cost to produce and distribute, more accessible. |
| Doses Required | Typically requires 2-4 shots for full immunity. | Usually requires one or a few doses for effective immunity. |


RBI’s Monetary Policy Committee Keeps Repo Rate at 5.25% Amid Global Turmoil – Implications for Inflation & Growth
5 Jun 2026
Retirement of RCP8.5 and Release of New Global Emission Scenarios – Implications for India’s Climate Policy
4 Jun 2026
Prime Minister highlights global popularity of Yoga as 1st World Yogasana Sports Championship commences in Ahmedabad, Gujarat
3 Jun 2026
India’s Equity Market Falls to 7th Globally as South Korea Overtakes in Market Capitalisation – June 2026
2 Jun 2026